TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Teva Pharmaceutical Industries Limited

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) concerning possible violations of federal securities laws.

On August 2, 2016, Teva completed its acquisition of Allergan plc’s generics business, Actavis Generis. Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. Then on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge. To obtain additional information, go to:

http://www.zlkdocs.com/TEVA-Info-Request-Form-6051

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
23/08/2017

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

February 20, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

February 17, 2026 1 EN
Si Yong Ng
  • Si Yong Ng
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
01/29/26 January 29, 2026 1 EN
Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
01/29/26 January 29, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

January 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch